Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625332 | 0.96 | RAB9A (0.58) | ALDH1A1SREBF2KMT2AMEN1RAB9A | |
| SCHEMBL12282550 | 0.85 | RAB9A (0.54) | ALDH1A1SREBF2KMT2AMEN1RAB9A | |
| SCHEMBL12490609 | 0.85 | KDM4E (0.54) | KMT2AMEN1RAB9AKDM4ENPC1 | |
| SCHEMBL12868318 | 0.82 | ATP4A (0.55) | ALDH1A1KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL19625300 | 0.81 | RAB9A (0.56) | ALDH1A1SREBF2KMT2AMEN1RAB9A | |
| SCHEMBL12282347 | 0.81 | LTA4H (0.58) | ALDH1A1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL533851 | 0.81 | GAA (0.40) | ALDH1A1SREBF2KMT2AMEN1RAB9A | |
| SCHEMBL19625353 | 0.81 | ATP4A (0.49) | ALDH1A1SREBF2KMT2AMEN1RAB9A | |
| SCHEMBL799889 | 0.81 | RAB9A (0.56) | ALDH1A1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL26014382 | 0.81 | RAB9A (0.58) | ALDH1A1KMT2AMEN1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200392259-A1 | ORTHOMETALLATED CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION AND COPOLYMERIZATION | ARZOUMANIDIS GREGORY G (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885SREBF2 125/4885KMT2A 4305/4885 |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ALDH1A1 3864/4885SREBF2 3136/4885KMT2A 4411/4885 |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885SREBF2 125/4885KMT2A 4305/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | ALDH1A1 3464/4885SREBF2 4531/4885KMT2A 3526/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | ALDH1A1 4217/4885SREBF2 3291/4885KMT2A 4324/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885SREBF2 1574/4885KMT2A 4200/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | ALDH1A1 2109/4885SREBF2 4581/4885KMT2A 3734/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | ALDH1A1 672/4885SREBF2 464/4885KMT2A 3518/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ALDH1A1 3864/4885SREBF2 3136/4885KMT2A 4411/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885SREBF2 125/4885KMT2A 4305/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885SREBF2 125/4885KMT2A 4305/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 1032/4885SREBF2 4346/4885KMT2A 3473/4885 |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | ALDH1A1 963/4885SREBF2 1249/4885KMT2A 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.